Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging : Frühwald MC, Rickert CH, O'Dorisio MS, Madsen M, Warmuth-Metz M, Khanna G, Paulus W, Kühl J, Jürgens H, Schneider P, Müller HL; Clin Cancer Res. 2004 May 1;10(9):2997-3006
    Active substance: (111In) INDIUM CHLORIDE/PENTETREOTIDE
    Study summary document link (including results):
    View full study record
    Document reference: 21232
    Study title: Patients with seasonal allergic rhinitis, conjunctivitis and possobly asthma symptoms so far only statistical analysis, Publication sheduled. Age of patients: 5 - 79 Years
    Active substance: 158 Rye
    Study summary document link (including results):
    View full study record
    Document reference: 39753
    Study title: ACARBOSE (BAY G 5421) IN INSULIN-DEPENDENT DIABETES - THE EFFECT ON THE DAILY BLOOD-GLUCOSE PROFILE AND ON THE INSULINCONSUMPTION BY AN ARTIFICIAL PANCREAS (STUDY 0160)(PH-9873)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0160_study_synopsis.pdf
    View full study record
    Document reference: 46154
    Study title: Clinical Study on the Efficacy and Tolerability of Acarbose (BAY g 5421) Compared with Placeboin Diabetic Children on Conventional Insulin Treatment, in Particular with Observation of the Glycemic Control Index ( PH-24820 )
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0665_study_synopsis.pdf
    View full study record
    Document reference: 46158
    Study title: Double-Blind, Cross-Over Clinical Study at a Single Centre to Compare Acarbose (BAY g 5421) with Placebo in Respect of Efficacy and Tolerability in Patients with Cystic Fibrosis and Pathological Glucose Tolerance (Pilot Study)(PH-26068)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0696_study_synopsis.pdf
    View full study record
    Document reference: 46159
    Study title: Blockers and hypoglycaemia (assesment of cadioselective and intrinsic sympathometic properties in relation to severity of hypoglycaemia - No author - 1984 (Current Therapeutic Research 36, n° 2, p. 361-373) ; - Publication in Documentation clinique du dossier d'AMM du 30/10/1987 -
    Active substance: ACEBUTOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 46182
    Study title: Clinical and echocardiographic (echo) long-term follow-up of children with severe hypertension (HT) - Loirat C. et al. - No date (Hopital Bretonneau, INSERM U 120, Paris) ; - Publication in Documentation clinique du dossier d'AMM du 30/10/1987 -
    Active substance: ACEBUTOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 46183
    Study title: Propanolol as an antihypertensive agent in children - Griswold W.R., Moneal R., Mendoza S.A. et al. - 1978 (Arch. Dis. Child. 537. pp 594-596) - Publication in Expertise clinique pour le dossier français de demande d'extension des indications thérapeutiques de Sectral 200 mg comprimés, au traitement de l'hypertension artérielle de l'enfant - Pr Broyer - 14/06/1983 -
    Active substance: ACEBUTOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 46189
    Study title: Spectral enfant – solution buvable à 40mg/ml – renseignements particuliers – partie V - No author - 01/10/1987
    Active substance: ACEBUTOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 46193
    Study title: Tolérance de 5 jours par voie orale chez le raton et le rat adulte suivie d’une période sans traitement de 15 jours (documentation toxicologique du dossier d’AMM du 30/10/87 du spectral enfant solution buvable 40mg/ml) - Briffaux - 02/10/1987
    Active substance: ACEBUTOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 46194
    Study title: Solcoderm study 006-I1: A double blind clinical comparison of Solcoderm with plain nitric acid of similar acid strnght." M. Weiner, Cincinatti, 1981, Solco-Study A clinical trial with Solcoderm, Authors: Haim S., Cohen A., Dec 1979, Israeli Study (summary)
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21248
    Study title: Solcoderm study 006-I2: "A double-blind evaluation of Solcoderm variants using pairs of comparable skin tumors."
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21249
    Study title: Action antipyrétique de l'acétylsalicylate de lysine (essai comparatif randomisé de trois posologies chez le jeune enfant) - JC Rolland, J. Papoin, C. Maurage, B. Caurier-1986 - Publication in the report N° FILIRF-FRZ0069-EN-E01 -
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46165
    Study title: Etude de l'absorption de l' "aspégic enfants nourissons" selon les modalités d'administration par voie orale - C. Dubray, A. Labbe, EJ Raynaud, M. Paire, J. Lavarenne - 1983 - Publication in the report N° FILIRF-FRZ0069-EN-E01 -
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46172
    Study title: Evaluation of ibuprofen versus Aspirin and Paracetamol on efficacy and comfort in children with fever - E. Autret, J. Reboul-Marty, B. Henry-Launois, C. Laborde, S. Courcier, JM Goehrs, G. Languillat, R. Launois - 1997 - Publication in the CES0079 - L. Baret-Cormel - 05 dec 2002 -
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46181
    Study title: Evaluation of ibuprofen versus Aspirin and Paracetamol on efficacy and comfort in children with fever - E. Autret, J. Reboul-Marty, B. Henry-Launois, C. Laborde, S. Courcier, JM Goehrs, G. Languillat, R. Launois - 1997 - Publication -
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46164
    Study title: Traitement des céphalées de l'encéphalographie gazeuse fractionnée par l'aspirine injectable - M. Sethian, MJ Rosset, JC Manelli, C Raybaud, J Fabre - 1972 - Publication in the report N° FILIRF-FRZ0069-EN-E01 -
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46177
    Study title: Short-time-immunotherapy with Allergoids, results from prospective, open Study in allergergological practices; Allergovit patients with seasonal rhino conjunctivitis and/or asthma symptoms Age of patients: 4 – 75 Years, 2047 Patients Allergologie, Jahrgang 28, Nr. 10/2005, S. 391-400
    Active substance: 006 Grasses (178 Kentucky Blue Grass, 179 Meadow Fescue, 140 Orchard Grass, 157 Rye Grass, 177 Timothy Grass, 133 Velvet Grass)
    Study summary document link (including results):
    View full study record
    Document reference: 39754
    Study title: Bladder pheochromocytoma: case presentation and the use of OctreoScan for localization of extra-adrenal tumour sites in a paediatric patientP R Health Sci J. 2008 Mar; 27(1):107-11
    Active substance: (111In) INDIUM CHLORIDE/PENTETREOTIDE
    Study summary document link (including results): 2011-09 GE Indium Chloride response List of published articles.doc
    View full study record
    Document reference: 48291
    Study title: Clinical use of somatostatin analogues in paediatric oncologyAlbers AR, O'Dorisio MS; . Digestion. 1996;57 Suppl 1:38-41.
    Active substance: (111In) INDIUM CHLORIDE/PENTETREOTIDE
    Study summary document link (including results):
    View full study record
    Document reference: 21233
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Aug 07 10:48:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA